| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 11th August 2020 | Eyal Rubin | 246,146 | Grant/award etc. | $0.00 | |
| 11th August 2020 | Dror Bashan | 447,927 | Grant/award etc. | $0.00 | |
| 7th April 2020 | Aharon Schwartz | 64,000 | Open or private purchase | $2.43 | $155,264.00 |
| 9th March 2020 | Aharon Schwartz | 112,200 | Sale back to the issuer | $0.00 |
Protalix Biotherapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins. It offers Taliglucerase alfa injections under the brand name Elelyso. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases.
Ticker: PLX
Sector: Health Services
Industry: Services to the Health Industry
SEC Central Index Key (CIK): 1006281
Employees: 196
Exchange: NYSE American
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $5 M (0%)
Inventory, Net: $11 M (0%)
Other Assets, Current: $3 M (57%)
Assets, Current: $54 M (66%)
Property, Plant and Equipment, Net: $5 M (-9%)
Assets: $72 M (57%)
Liabilities, Current: $42 M (5%)
Other Liabilities, Noncurrent: $124 Th (-75%)
Liabilities: $106 M (-7%)
Stockholders' Equity (Parent): $35 M (0%)
Liabilities and Equity: $72 M (57%)
Research and Development: $9 M (-52%)
Operating Income/Loss: $2 M (-8%)
Other Income, net: $2 M (-61%)
